CL2017000191A1 - Método - Google Patents

Método

Info

Publication number
CL2017000191A1
CL2017000191A1 CL2017000191A CL2017000191A CL2017000191A1 CL 2017000191 A1 CL2017000191 A1 CL 2017000191A1 CL 2017000191 A CL2017000191 A CL 2017000191A CL 2017000191 A CL2017000191 A CL 2017000191A CL 2017000191 A1 CL2017000191 A1 CL 2017000191A1
Authority
CL
Chile
Prior art keywords
subject
agent
administrating
union
therapy
Prior art date
Application number
CL2017000191A
Other languages
English (en)
Inventor
Christian Kjellman
Sofia Jarnum
Lena Winstedt
Original Assignee
Hansa Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansa Medical Ab filed Critical Hansa Medical Ab
Publication of CL2017000191A1 publication Critical patent/CL2017000191A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

<p>LA INVENCIÓN SE REFIERE A UN MÉTODO PARA MEJORAR EL BENEFICIO DE UNA TERAPIA O UN AGENTE TERAPÉUTICO PARA UN SUJETO. EL MÉTODO COMPRENDE (A) ADMINISTRAR AL SUJETO UN AGENTE QUE REDUCE LIA UNIÓN AL RECEPTOR Fc DE MOLÉCULAS DE IgG EN SUERO EN EL SUJETO; Y ADMINISTRAR POSTERIORMENTE DICHA TERAPIA O DICHO AGENTE TERAPÉUTICO AL SUJETO. LA INVENCIÓN SE REFIERE TAMBIÉN A UN MÉTODO PARA REDUCIR EL EFECTO DE AUTOANTICUERPOS PATÓGENOS EN UN SUJETO, COMPRENDIENDO EL MÉTODO (A) ADMINISTRAR AL SUJETO UN AGENTE QUE REDUCE LA UNIÓN AL RECEPTOR DE Fc DE MOLÉCULAS DE IgG EN SUERO EN EL SUJETO Y OPCIONALMENTE (B) SOMETER SUBSECUENTEMENTE AL SUJETO A UN TRATAMIENTO QUE ELIMINA AUTOANTICUERPOS ENDÓGENOS. LA INVENCIÓN SE REFIERE TAMBIÉN A UN KIT PARA LLEVAR A CABO UN MÉTODO DE LA INVENCIÓN.</p>
CL2017000191A 2014-07-25 2017-01-25 Método CL2017000191A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1413240.1A GB201413240D0 (en) 2014-07-25 2014-07-25 Method

Publications (1)

Publication Number Publication Date
CL2017000191A1 true CL2017000191A1 (es) 2017-08-25

Family

ID=51587261

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000191A CL2017000191A1 (es) 2014-07-25 2017-01-25 Método

Country Status (19)

Country Link
US (2) US10973889B2 (es)
EP (1) EP3171891A2 (es)
JP (1) JP6708641B2 (es)
KR (2) KR20230119267A (es)
CN (2) CN114949187A (es)
AU (1) AU2015294125B2 (es)
BR (1) BR112017001420A2 (es)
CA (1) CA2955704A1 (es)
CL (1) CL2017000191A1 (es)
CO (1) CO2017000571A2 (es)
EA (1) EA039169B1 (es)
GB (1) GB201413240D0 (es)
HK (1) HK1232122A1 (es)
IL (1) IL249981B (es)
MX (1) MX2017001138A (es)
MY (1) MY196858A (es)
NZ (1) NZ728265A (es)
SG (1) SG11201700172WA (es)
WO (1) WO2016012285A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US10434141B2 (en) 2016-05-31 2019-10-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
AU2020323542A1 (en) * 2019-08-01 2022-03-17 Memorial Hospital For Cancer And Allied Diseases Cells for improved immunotherapy and uses thereof
AU2020319897A1 (en) * 2019-08-01 2022-02-24 Momenta Pharmaceuticals, Inc. FcRn antibodies and methods of use thereof
IL295070A (en) 2020-01-28 2022-09-01 Freeline Therapeutics Ltd An improved test for determining the value of neutralizing antibodies to a viral vector
GB202003129D0 (en) * 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
GB202007434D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
CN115515631A (zh) * 2020-09-21 2022-12-23 上海宝济药业有限公司 一种药物组合及其应用
US20230374542A1 (en) 2020-10-07 2023-11-23 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
AU2022256479A1 (en) 2021-04-16 2023-11-30 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
CA3237815A1 (en) 2021-11-15 2023-05-19 Raghuveer RANGANATHAN Methods for enhancing adoptive cell transfer immunotherapies
WO2023175498A1 (en) 2022-03-17 2023-09-21 Pfizer Inc. Improved igg-degrading enzymes and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
JPH0612624B2 (ja) * 1984-06-20 1994-02-16 株式会社日立製作所 半導体集積回路装置
US6006752A (en) * 1996-05-09 1999-12-28 The General Hospital Corporation Mixed chimerism and tolerance
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
EP1901773B1 (en) 2005-06-09 2012-03-07 Hansa Medical AB Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection
GB2427360A (en) * 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
GB0624874D0 (en) * 2006-12-13 2007-01-24 Hansa Medical Ab Treatment
DK2190984T3 (da) * 2007-09-14 2013-12-02 Genovis Ab Fremgangsmåder og kits til oprensning og påvisning af glycosyleret IgG
GB201115841D0 (en) * 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) 2012-01-26 2012-03-07 Isis Innovation Composition
TWI626491B (zh) 2012-12-10 2018-06-11 布萊恩荷登視覺協會 用於視力校正之具有一或多個多正焦區域之眼用光學透鏡

Also Published As

Publication number Publication date
IL249981B (en) 2022-08-01
SG11201700172WA (en) 2017-02-27
CN106714834A (zh) 2017-05-24
KR20170039243A (ko) 2017-04-10
WO2016012285A3 (en) 2016-04-14
CN114949187A (zh) 2022-08-30
WO2016012285A2 (en) 2016-01-28
HK1232122A1 (zh) 2018-01-05
US20170209550A1 (en) 2017-07-27
EP3171891A2 (en) 2017-05-31
US10973889B2 (en) 2021-04-13
AU2015294125B2 (en) 2020-10-15
CO2017000571A2 (es) 2017-06-20
CA2955704A1 (en) 2016-01-28
KR102565244B1 (ko) 2023-08-10
KR20230119267A (ko) 2023-08-16
JP6708641B2 (ja) 2020-06-10
IL249981A0 (en) 2017-03-30
EA201790192A1 (ru) 2017-09-29
US20210260173A1 (en) 2021-08-26
EA039169B1 (ru) 2021-12-13
MX2017001138A (es) 2017-06-07
BR112017001420A2 (pt) 2017-11-28
MY196858A (en) 2023-05-05
JP2017522384A (ja) 2017-08-10
GB201413240D0 (en) 2014-09-10
NZ728265A (en) 2024-03-22
AU2015294125A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
CL2017000191A1 (es) Método
EA201891983A8 (ru) Комбинированная терапия антителами к cd73
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
CR20190350A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
GEP20217252B (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
AU2017310412A8 (en) Method of improving connective tissue attachment using anti-sclerostin antibodies
EA201591513A1 (ru) Терапевтическое применение антител к vegfr1 (варианты)
MX2020003563A (es) Anticuerpo anti-pacap.
EA201990978A1 (ru) Антитела против pd-1
CL2021002866A1 (es) Tratamiento de la cefalea usando anticuerpos anti-cgrp.
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
EA202090260A1 (ru) Средства и способы для генотерапии aav у человека
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas
WO2018129451A3 (en) Anti-fgfr antibodies and methods of use